__NUXT_JSONP__("/drugs/Alacizumab_Pegol", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"934216-54-3",chebiId:b,chemicalFormula:b,definition:"A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.",fdaUniiCode:"ZL9780F883",identifier:"C61438",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1971"],synonyms:["ALACIZUMAB PEGOL",c,"CDP-791"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAlacizumab_Pegol",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Alacizumab_Pegol","","Alacizumab Pegol","2021-10-30T13:41:30.103Z")));